Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 1

Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH)

Authors Angelo J Cambio, Christopher P Evans

Published 15 March 2007 Volume 2007:3(1) Pages 181—196

Angelo J Cambio, Christopher P Evans

Department of Urology [A.J.C., C.P.E.], University of California, Davis, Sacramento, CA, USA

Background: Benign prostatic hyperplasia (BPH) is a common disease of the aging male population. BPH treatment includes a variety of pharmacological and surgical interventions. The goal of this paper is to review the natural history of BPH, outcomes of pharmacological management, effects on quality of life (QoL), future pharmacotherapies, and associated patient-focused perspectives.

Materials and methods: Medline searches for the keywords benign prostatic hyperplasia, BPH, alpha blockers, 5 alpha-reductase, and quality of life were performed. Relevant literature was reviewed and analyzed.

Results: Alpha blockers, 5 alpha-reductase inhibitors, and phytotherapy are the three categories of pharmaceutical interventions currently available for BPH. Various clinical trials have shown that alpha blockers and 5 alpha-reductase inhibitors are safe, efficacious, and improve QoL in patients with BPH. The evidence for phytotherapeutics is not as convincing. The current armamentarium of pharmaceutical interventions are encompassed in these three classes of medications. New pharmacotherapies based on novel mechanisms are on the horizon.

Conclusion: There are a variety of safe and efficacious medical therapies available for the management of BPH and it is important for the practicing physician to have an understanding of these pharmacotherapies and their potential impact on the patient. There is not enough evidence to make a recommendation regarding phytotherapy use. New classes of drugs for BPH will likely find their way into routine use.

Keywords: Benign prostatic hyperplasia, benign prostatic hypertrophy, BPH, alpha blockers, 5 alpha-reductase inhibitor, quality of life.

Download Article [PDF] 

Readers of this article also read:

Induction of long noncoding RNA MALAT1 in hypoxic mice

Lelli A, Nolan KA, Santambrogio S, Gonçalves AF, Schönenberger MJ, Guinot A, Frew IJ, Marti HH, Hoogewijs D, Wenger RH

Hypoxia 2015, 3:45-52

Published Date: 8 October 2015

Simvastatin enhances Rho/actin/cell rigidity pathway contributing to mesenchymal stem cells’ osteogenic differentiation

Tai IC, Wang YH, Chen CH, Chuang SC, Chang JK, Ho ML

International Journal of Nanomedicine 2015, 10:5881-5894

Published Date: 21 September 2015

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate

Omar S Din, Penella J Woll

Therapeutics and Clinical Risk Management 2008, 4:149-162

Published Date: 8 February 2008

Etanercept in the treatment of rheumatoid arthritis

Boulos Haraoui, Vivian Bykerk

Therapeutics and Clinical Risk Management 2007, 3:99-105

Published Date: 15 March 2007

Optimal timing for antihypertensive dosing: focus on valsartan

Ramón C Hermida, Diana E Ayala, Carlos Calvo

Therapeutics and Clinical Risk Management 2007, 3:119-131

Published Date: 15 March 2007

Willingness-to-pay for caregivers of children with asthma or wheezing conditions

Stefan Walzer, Peter Zweifel

Therapeutics and Clinical Risk Management 2007, 3:157-165

Published Date: 15 March 2007

Acne phototherapy with a 1450-nm diode laser: an open study

Natusko Konishi, Hideki Endo, Naoki Oiso, Shigeru Kawara, Akira Kawada

Therapeutics and Clinical Risk Management 2007, 3:205-209

Published Date: 15 March 2007